Latest News & Updates

Breaking News

  • 2 hours ago

  • Pharma Now Editorial Team

Sanofi's Nuvaxovid Shows Lower Reactogenicity Than mRNA Rival in Phase 4 Trial
Breaking News
Bispecific PD-1xVEGF Data in NSCLC Raises Scale-Up Questions for Merck

Pharma Now Editorial Team

Other trending news you may like to read

Sanofi's Nuvaxovid Shows Lower Reactogenicity Than mRNA Rival in Phase 4 Trial

Sanofi's COMPARE Phase 4 trial shows Nuvaxovid has statistically significant lower reactogenicity than Moderna's mNEXSPIKE across all endpoints.

Pharma Now Editorial Team

Pharma Now

Bispecific PD-1xVEGF Data in NSCLC Raises Scale-Up Questions for Merck

Merck shares early PD-1xVEGF bispecific data in NSCLC but withholds phase 3 plans, raising questions about GMP scale-up readiness.

Pharma Now Editorial Team

Pharma Now

Oral Biologics Push Forces Rethink of Formulation and Manufacturing

Oral biologics and macrocycle drugs are driving new formulation and manufacturing demands that pharma plants must prepare for now.

Pharma Now Editorial Team

Pharma Now

Nasal Epinephrine Approval Signals GMP Shifts for Delivery Reformulations

ARS Pharma's nasal epinephrine approval highlights GMP, process validation, and regulatory challenges facing manufacturers pursuing delivery reformulations.

Pharma Now Editorial Team

Pharma Now